{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:25:16Z","timestamp":1792445116408,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.blre.2025.101343","type":"journal-article","created":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T22:58:37Z","timestamp":1762124317000},"page":"101343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Redefining central nervous system multiple myeloma: From rare phenomenon to emerging entity"],"prefix":"10.1016","volume":"74","author":[{"given":"Ian","family":"Landry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam F.","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Yorker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.blre.2025.101343_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0609.2007.00956.x","article-title":"Central nervous system myelomatosis: review of the literature","volume":"80","author":"Nieuwenhuizen","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2025.101343_bb0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41408-022-00643-3","article-title":"Extramedullary disease in multiple myeloma: a systematic literature review","volume":"12","author":"Blad\u00e9","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.blre.2025.101343_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-019-0660-0","article-title":"Extramedullary multiple myeloma","volume":"34","author":"Bhutani","year":"2020","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.blre.2025.101343_bb0020","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/ajh.24351","article-title":"Central nervous system involvement by multiple myeloma: a multi-institutional retrospective study of 172 patients","volume":"91","author":"Jurczyszyn","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101343_bb0025","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/10428190310001597964","article-title":"Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities","volume":"45","author":"Fassas","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.blre.2025.101343_bb0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjh.12414","article-title":"CNS involvement with multiple myeloma: long-term survival with radiation, intrathecal chemotherapy, and immunomodulatory agents","volume":"162","author":"Chen","year":"2013","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.blre.2025.101343_bb0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bjh.14498","article-title":"Marizomib for central nervous system-multiple myeloma","volume":"177","author":"Badros","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2025.101343_bb0040","series-title":"SEER*stat database: incidence - SEER research data, 8 registries, Nov 2023 sub (1975-2021)","author":"Surveillance, Epidemiology, and End Results (SEER) Program","year":"2024"},{"issue":"7","key":"10.1016\/j.blre.2025.101343_bb0045","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3324\/haematol.2020.248518","article-title":"Multiple myeloma with central nervous system relapse","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.blre.2025.101343_bb0050","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood.V86.11.4250.bloodjournal86114250","article-title":"Poor prognosis in multiple myeloma is associated with deletions of chromosome 13 or abnormalities involving 11q","volume":"86","author":"Tricot","year":"1995","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.blre.2025.101343_bb0055","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2141.2004.05199.x","article-title":"Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions","volume":"127","author":"Chang","year":"2004","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.blre.2025.101343_bb0060","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1001\/archneur.61.9.1423","article-title":"Multiple myeloma invasion of the central nervous system","volume":"61","author":"Schluterman","year":"2004","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.blre.2025.101343_bb0065","first-page":"1402","article-title":"Clinical features of multiple myeloma invasion of the central nervous system in Chinese patients","volume":"123","author":"Qu","year":"2010","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"10.1016\/j.blre.2025.101343_bb0070","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1002\/hon.1021","article-title":"Emergence of central nervous system myeloma in the era of novel agents","volume":"30","author":"Gangatharan","year":"2012","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101343_bb0075","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/cncr.26447","article-title":"Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: a retrospective survey of 50 patients","volume":"118","author":"Gozzetti","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.blre.2025.101343_bb0080","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bjh.12404","article-title":"CNS multiple myeloma\u2014roles for intrathecal therapy and CSF light chains","volume":"162","author":"Lee","year":"2013","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2025.101343_bb0085","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjh.12670","article-title":"Central nervous system multiple myeloma: a different cytogenetic profile?","volume":"164","author":"Chang","year":"2014","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2025.101343_bb0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.clml.2013.11.004","article-title":"Patterns of central nervous system involvement in relapsed and refractory multiple myeloma","volume":"14","author":"Abdallah","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.blre.2025.101343_bb0095","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.clml.2015.02.028","article-title":"Diagnostic utility of measuring free light chains in cerebrospinal fluid of patients with multiple myeloma","volume":"15","author":"Marron","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"12","key":"10.1016\/j.blre.2025.101343_bb0100","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00277-015-2484-y","article-title":"Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience","volume":"94","author":"Katodritou","year":"2015","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.blre.2025.101343_bb0105","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.clml.2016.08.010","article-title":"Myelomatous involvement of the central nervous system","volume":"16","author":"Paludo","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.blre.2025.101343_bb0110","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.bjhh.2017.09.004","article-title":"Multiple myeloma and central nervous system involvement: experience of a Brazilian center","volume":"40","author":"Dias","year":"2018","journal-title":"Hematol Transfus Cell Ther"},{"key":"10.1016\/j.blre.2025.101343_bb0115","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/3970169","article-title":"Multiple myeloma of the central nervous system: 13 cases and review of the literature","volume":"2018","author":"Varga","year":"2018","journal-title":"J Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101343_bb0120","doi-asserted-by":"crossref","first-page":"S146","DOI":"10.1016\/S2152-2650(21)02324-7","article-title":"Central nervous system multiple myeloma (CNS-MM), presentation and outcomes in an era of anti-CD38 and pomalidomide inclusive therapies","volume":"21","author":"Khan","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"22","key":"10.1016\/j.blre.2025.101343_bb0125","doi-asserted-by":"crossref","first-page":"4493","DOI":"10.1182\/blood.V128.22.4493.4493","article-title":"Central nervous system invasion in multiple myeloma: a nationwide survey of 75 patients in Japan","volume":"128","author":"Yamashita","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101343_bb0130","article-title":"Central nervous system manifestations as initial presentation of plasma cell disorders: different management of 3 cases based on disease extent","volume":"11","author":"McGrath","year":"2023","journal-title":"Curr Probl Cancer: Case Rep"},{"issue":"3","key":"10.1016\/j.blre.2025.101343_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.07.1473","article-title":"Outcome of patients with central nervous system multiple myeloma (CNS-MM) treated with CNS-directed radiation therapy","volume":"144","author":"Manzar","year":"2022","journal-title":"Int J Radiat Oncol"},{"issue":"9","key":"10.1016\/j.blre.2025.101343_bb0140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41408-021-00527-y","article-title":"Extramedullary disease in multiple myeloma","volume":"11","author":"Bansal","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.blre.2025.101343_bb0145","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00277-016-2847-z","article-title":"The possible role of burden of therapy on the risk of myeloma extramedullary spread","volume":"96","author":"Mangiacavalli","year":"2017","journal-title":"Ann Hematol"},{"issue":"28","key":"10.1016\/j.blre.2025.101343_bb0150","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.blre.2025.101343_bb0155","doi-asserted-by":"crossref","first-page":"7301","DOI":"10.3390\/ijms26157301","article-title":"Breaking barriers: the role of the bone marrow microenvironment in multiple myeloma progression","volume":"26","author":"Agafonova","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.blre.2025.101343_bb0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","article-title":"Extramedullary disease in multiple myeloma - controversies and future directions","volume":"36","author":"Sevcikova","year":"2019","journal-title":"Blood Rev"},{"issue":"3","key":"10.1016\/j.blre.2025.101343_bb0165","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1096\/fj.06-6610com","article-title":"Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential","volume":"21","author":"Tohami","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.blre.2025.101343_bb0170","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12987-025-00618-z","article-title":"Breaking boundaries: role of the brain barriers in metastatic process","volume":"22","author":"Izadi","year":"2025","journal-title":"Fluids Barriers CNS"},{"issue":"1","key":"10.1016\/j.blre.2025.101343_bb0175","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa021","article-title":"Bortezomib at therapeutic doses poorly passes the blood-brain barrier and does not impair cognition","volume":"2","author":"Huehnchen","year":"2020","journal-title":"Brain Commun"},{"issue":"4","key":"10.1016\/j.blre.2025.101343_bb0180","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/cancers12041035","article-title":"Carfilzomib-based strategies in relapsed\/refractory multiple myeloma with extramedullary disease","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.blre.2025.101343_bb0185","article-title":"Multiple myeloma with isolated central nervous system relapse after autologous stem cell transplantation: a case report and review of the literature","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"22","key":"10.1016\/j.blre.2025.101343_bb0190","doi-asserted-by":"crossref","first-page":"5704","DOI":"10.1182\/blood.V128.22.5704.5704","article-title":"Report of 5 cases of extramedullary myeloma with central nervous system relapse [abstract]","volume":"128","author":"Espinoza","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2025.101343_bb0195","article-title":"Case reports: central nervous system involvement in patients with newly diagnosed multiple myeloma","volume":"14","author":"Liu","year":"2023","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.blre.2025.101343_bb0200","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/neuonc\/nov299","article-title":"Marizomib activity as a single agent in malignant gliomas: ability to cross the blood\u2013brain barrier","volume":"18","author":"Di","year":"2016","journal-title":"Neuro-Oncology"},{"issue":"18","key":"10.1016\/j.blre.2025.101343_bb0205","doi-asserted-by":"crossref","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-15-2616","article-title":"Phase I clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052-102 final results","volume":"22","author":"Harrison","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"22","key":"10.1016\/j.blre.2025.101343_bb0210","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1182\/blood-2015-12-686378","article-title":"Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma","volume":"127","author":"Mateos","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.blre.2025.101343_bb0215","doi-asserted-by":"crossref","DOI":"10.3892\/mco.2021.2360","article-title":"IgD multiple myeloma with central nervous system involvement: a case report and literature review","volume":"15","author":"Chen","year":"2021","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2025.101343_bb0220","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00280-011-1781-y","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates","volume":"69","author":"Muscal","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.blre.2025.101343_bb0225","article-title":"Secondary CNS myeloma with remission after systemic CNS-penetrating agents","volume":"4","author":"Fernandez","year":"2022","journal-title":"Neuro-Oncol Adv"},{"issue":"10","key":"10.1016\/j.blre.2025.101343_bb0230","first-page":"2071","article-title":"Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies","volume":"101","author":"Ogiya","year":"2022","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.blre.2025.101343_bb0235","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/16078454.2021.2019364","article-title":"Pomalidomide-based therapy for extramedullary multiple myeloma","volume":"27","author":"Li","year":"2022","journal-title":"Hematology"},{"issue":"6","key":"10.1016\/j.blre.2025.101343_bb0240","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2011.29","article-title":"Incidence of extramedullary disease in MM and activity of pomalidomide","volume":"25","author":"Short","year":"2011","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.blre.2025.101343_bb0245","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.13217","article-title":"Pomalidomide-dexamethasone for soft-tissue plasmacytomas in relapsed\/refractory MM","volume":"102","author":"Jim\u00e9nez-Segura","year":"2019","journal-title":"Eur J Haematol"},{"issue":"23","key":"10.1016\/j.blre.2025.101343_bb0250","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1182\/blood.V126.23.1789.1789","article-title":"Resistance to lenalidomide in multiple myeloma is associated with a switch in gene expression profile","volume":"126","author":"Amatangelo","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.blre.2025.101343_bb0255","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.3324\/haematol.2017.186601","article-title":"Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patients","volume":"103","author":"Laurens","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2025.101343_bb0260","first-page":"2227","article-title":"Resistance to immunomodulatory drugs in multiple myeloma","volume":"107","author":"Gooding","year":"2022","journal-title":"Haematologica"},{"issue":"Suppl","key":"10.1016\/j.blre.2025.101343_bb0265","doi-asserted-by":"crossref","first-page":"S289","DOI":"10.1016\/j.clml.2018.07.229","article-title":"The daratumumab crosses the blood brain barrier","volume":"18","author":"Vercruyssen","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.blre.2025.101343_bb0270","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000413","article-title":"Cerebrospinal fluid penetrance of daratumumab in leptomeningeal multiple myeloma","volume":"4","author":"Zajec","year":"2020","journal-title":"HemaSphere"},{"issue":"15_suppl","key":"10.1016\/j.blre.2025.101343_bb0275","article-title":"Evaluation of blood-brain barrier penetration properties of daratumumab in a patient with central nervous system involvement of extranodal natural killer\/T-cell lymphoma","volume":"41","author":"Dapkeviciute-Purliene","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2025.101343_bb0280","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3892\/or.2022.8325","article-title":"Bendamustine: pharmacology, clinical use and immunological effects","volume":"47","author":"Lalic","year":"2022","journal-title":"Oncol Rep"},{"key":"10.1016\/j.blre.2025.101343_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.934240","article-title":"Central nervous system myeloma and unusual extramedullary localizations: real life practical guidance","volume":"12","author":"Sammartano","year":"2022","journal-title":"Front Oncol"},{"issue":"Suppl. 16","key":"10.1016\/j.blre.2025.101343_bb0290","volume":"43","author":"Alam","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2025.101343_bb0295","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.7150\/thno.40908","article-title":"Effects of dexamethasone on BBB permeability after focused ultrasound","volume":"10","author":"McMahon","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.blre.2025.101343_bb0300","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40259-021-00514-6","article-title":"Targeting nuclear export proteins in multiple myeloma therapy","volume":"36","author":"Richard","year":"2022","journal-title":"BioDrugs"},{"issue":"8","key":"10.1016\/j.blre.2025.101343_bb0305","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa1903455","article-title":"Oral selinexor-dexamethasone for triple-class refractory multiple myeloma","volume":"381","author":"Chari","year":"2019","journal-title":"N Engl J Med"},{"issue":"10262","key":"10.1016\/j.blre.2025.101343_bb0310","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.blre.2025.101343_bb0315","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1177\/10781552241235902","article-title":"Selinexor for the treatment of patients with relapsed or refractory multiple myeloma","volume":"30","author":"Babar","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.blre.2025.101343_bb0320","series-title":"SPODUMENE (NCT05478993)","year":"2025"},{"issue":"18","key":"10.1016\/j.blre.2025.101343_bb0325","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.3390\/cancers13184666","article-title":"Rapid progress in the use of immunomodulatory drugs and cereblon E3 ligase modulators in the treatment of multiple myeloma","volume":"13","author":"Charli\u0144ski","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.blre.2025.101343_bb0330","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","volume":"389","author":"Richardson","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2025.101343_bb0335","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/CJI.0000000000000391","article-title":"BCMA CAR-T therapy for CNS involvement in relapsed MM","volume":"45","author":"Wang","year":"2022","journal-title":"J Immunother"},{"key":"10.1016\/j.blre.2025.101343_bb0340","article-title":"Successful BCMA CAR-T therapy for multiple myeloma with central nervous system involvement manifesting as cauda equina syndrome-a wandering road to remission","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.blre.2025.101343_bb0345","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1182\/bloodadvances.2024014345","article-title":"BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement","volume":"9","author":"Gaballa","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2025.101343_bb0350","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","article-title":"Preclinical activity of JNJ-7957 BCMA\u00d7CD3 bispecific potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.blre.2025.101343_bb0355","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a GPRC5D bispecific antibody for MM","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"10.1016\/j.blre.2025.101343_bb0360","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e19505","article-title":"Bispecific antibody therapy in central nervous system (CNS) multiple myeloma (MM): multicenter retrospective study","volume":"43","author":"Noveihed","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2025.101343_bb0365","first-page":"890","article-title":"Impact of extramedullary disease in newly diagnosed MM undergoing ASCT","volume":"103","author":"Gagelmann","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.blre.2025.101343_bb0370","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating tumor DNA profiling for brain lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2025.101343_bb0375","first-page":"513","article-title":"Cell-free ctDNA in CSF for CNS B-cell lymphomas","volume":"106","author":"Bobillo","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2025.101343_bb0380","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2023.1611171","article-title":"Soluble BCMA as a monitoring marker for MM","volume":"29","author":"Wiedemann","year":"2023","journal-title":"Pathol Oncol Res"},{"issue":"6","key":"10.1016\/j.blre.2025.101343_bb0385","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","article-title":"Serum BCMA is elevated in MM and correlates with disease status","volume":"158","author":"Sanchez","year":"2012","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2025.101343_bb0390","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/bjh.14145","article-title":"BCMA as a target for ADC-mediated cytotoxicity in MM","volume":"174","author":"Lee","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2025.101343_bb0395","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11523-021-00821-6","article-title":"Serum BCMA levels indicate clinical status in RRMM","volume":"16","author":"Bujarski","year":"2021","journal-title":"Target Oncol"},{"issue":"24","key":"10.1016\/j.blre.2025.101343_bb0400","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1200\/JCO-24-01893","article-title":"International myeloma society\/international myeloma working group consensus recommendations on the definition of high-risk multiple myeloma","volume":"43","author":"Avet-Loiseau","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2025.101343_bb0405","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.clml.2024.11.010","article-title":"Outcome of patients with central nervous system multiple myeloma (CNS-MM) treated with CNS-directed radiation therapy","volume":"25","author":"Manzar","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000888?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X25000888?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T17:37:51Z","timestamp":1766079471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X25000888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":81,"alternative-id":["S0268960X25000888"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2025.101343","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redefining central nervous system multiple myeloma: From rare phenomenon to emerging entity","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2025.101343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101343"}}